The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Valve-in-valve TAVR using the SAPIEN 3 transcatheter heart valve: still plagued by patient-prosthesis mismatch

EuroIntervention 2018;14:e377-e379 published online e-edition July 2018. DOI: 10.4244/EIJV14I4A66

1. Saint Luke’s Mid America Heart Institute, Kansas City, MO, USA; 2. University of Missouri, Kansas City School of Medicine, Kansas City, MO, USA; 3. NorthShore University Health System, Evanston, IL, USA

Valve-in-valve (VinV) transcatheter aortic valve replacement (TAVR) has become a well-established therapy for patients with failed surgical bioprosthetic valves (BPV) who are at high risk for reoperation1. In the largest series to date, VinV TAVR demonstrated a one-year survival rate of 83.2%, which was similar to that of patients undergoing native aortic stenosis (AS) TAVR in high-risk populations2,3. Of note, in that series, most patients (53.4%) were treated with a second-generation balloon-expandable transcatheter heart valve (THV), namely the SAPIEN XT THV (Edwards Lifesciences, Irvine, CA, USA).

Over the decade since its introduction for the treatment of native AS, iterative modifications ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
TAVI durability beyond five years: no alarms, but stay alert